American Society of Nephrology (ASN) Kidney Week 2025

Individuals with end-stage kidney disease (ESKD) who have mild-to-severe constipation obtain relief from tenapanor in the post hoc analysis of the phase III BLOCK study.

Treatment with telitacicept led to a significant reduction in proteinuria among patients with immunoglobulin A nephropathy (IgAN) compared with placebo, according to a phase III study presented at ASN Kidney Week 2025.

In the post hoc analysis of the phase III PROTECT trial, the non-immunosuppressive dual endothelin angiotensin receptor antagonist sparsentan remains superior to irbesartan for the treatment of immunoglobulin A nephropathy (IgAN).

In hospitalized patients with acute kidney injury (AKI) requiring dialysis (AKI-D), a conservative strategy appears to lead to more frequent and faster kidney function recovery with fewer dialysis sessions compared with a conventional strategy, as shown in the LIBERATE-D trial.

Treatment with the self-administered atacicept injectable yields a significant reduction in proteinuria in patients with IgA nephropathy, according to interim data from the phase III ORIGIN 3 trial.